Docent Pekka Postila and Professor Olli Pentikäinen from the Institute of Biomedicine and InFLAMES Flagship have received 100,000 dollars in funding from the SynGAP Research Fund (SRF) for SynGAP syndrome research.
Through immunotherapies utilising Immune Checkpoint Blockers (ICB), advanced solid cancers can today be treated with unprecedented efficacy. However, not all patients respond positively to these treatments. InFLAMES researcher, Docent Carlos Rogerio Figueiredo and his team are working to uncover the underlying causes of this resistance to ICB. They focus on patients suffering from malignant melanomas and lung cancers as main research models.
New technologies aim to find revolutionary ways to diagnose, treat and prevent diseases. The second InFLAMES Flagship Corporate Corner of 2023 will focus on the topic from the perspectives of both researchers and companies. The InFLAMES Corporate Corner will take place on 11th May from 12 to 16 at the Visitor and Innovation Centre Joki in Turku. The event is open to all.
A new nasal pertussis vaccine against whooping cough has shown promising results. The vaccine was shown to be safe and to work against whooping cough in a study conducted in healthy adults. Professor Qiushui He and Project Researcher Alex-Mikael Barkoff from the InFLAMES research flagship of the University of Turku participated in the study. The research article was published in the esteemed medical journal Lancet.
What is sustainability within health, diagnostics and drug development? What are the environmental impacts of medication and food? What are the ethical decisions in relation to the cost of medication?
An international team of researchers has discovered how the so-called tertiary lymphoid-like structures can help the human immune defence to find cancer cells and destroy them. Researchers from the InFLAMES research flagship of the University of Turku, Finland, participated in the study and the research article was published in the esteemed Cancer Cell journal.